Key result
Edoxaban matches warfarin for thromboembolism prevention with ~21% lower risk and less major bleeding.
Why the study?
With the emergence of edoxaban and changing guidelines reflecting an increased choice of NOACs over VKAs for stroke prevention in non-valvular AF, clinicians must consider which anticoagulant offers the best therapy for their patients.
Does edoxaban provide non-inferior stroke and systemic embolism prevention with lower bleeding risk compared with warfarin in patients with non-valvular atrial fibrillation?
Does edoxaban provide non-inferior stroke and systemic embolism prevention with lower bleeding risk compared with warfarin in patients with non-valvular atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Edoxaban 60 mg and 30 mg once daily offer non-inferior stroke prevention and significantly lower major bleeding, intracranial haemorrhage, and cardiovascular mortality compared with warfarin, complementing current atrial fibrillation guidelines with a flexible once-daily dosing option.
With the emergence of edoxaban, the oral factor Xa inhibitors now appear consolidated as the dominant class of novel oral anticoagulants (NOACs) for stroke prevention in non-valvular atrial fibrillation (AF). The oral factor Xa inhibitors do not require an adequate time in therapeutic range to be effective, presenting a potential advantage over the vitamin K antagonists (VKAs). Guidelines are changing to reflect the increased choice of anticoagulants and as clinicians move away from the VKAs towards the relative safety and efficacy of NOACs, they must consider which one offers the best therapy for their patient. The ENGAGE-AF study was the latest phase III trial to report on the safety and efficacy of a new factor Xa inhibitor relative to warfarin. Both edoxaban 60mg once daily, and edoxaban 30mg once daily were found to be non-inferior compared to warfarin for the prevention of ischaemic stroke and systemic embolism, being associated with significantly lower rates of major bleeding, intracranial haemorrhage and cardiovascular death. A two-tiered dosing option may present clinicians with a further element of choice for the individual patient.
No takes yet. Share an insight, caveat, or question.
Plunkett et al. (2011) conducted a review in Non-valvular atrial fibrillation. Edoxaban vs. Warfarin (titrated to INR 2.0-3.0) and other novel oral anticoagulants was evaluated on Stroke or systemic embolism (HR 0.79, 95% CI 0.63-0.99). Edoxaban and once daily were non-inferior to warfarin for preventing stroke or systemic embolism with less major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: